Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
The Surgical Clinics of North America
|
May 27, 2014
Evaluation of thyroid incidentaloma
Scott Wilhelm
Current Pharmaceutical Design
|
October 9, 2002
BAY 43-9006: preclinical data
Scott Wilhelm, Du-Shieng Chien
Rare Tumors
|
July 20, 2011
Adrenal adenomatoid tumor in a patient with human immunodeficiency virus
Roy Phitayakorn, Gregory Maclennan, Peter Sadow, et al.
Seminars in Oncology
|
August 8, 2006
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway
Jared A Gollob, Scott Wilhelm, Chris Carter, et al.
International Journal of Surgical Pathology
|
March 13, 2026
Parathyroid Carcinoma Mimicking Thyroid Hyalinizing Trabecular Tumor: A Case Report and Review of Atypical Presentations of Parathyroid Carcinoma
Paola Loreto-Palacio, Myriam Decaussin-Petrucci, Scott Wilhelm, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
|
March 14, 2009
Utilization of preoperative patient factors to predict postoperative vitamin D deficiency for patients undergoing gastric bypass
Judy Jin, Thomas A Stellato, Peter T Hallowell, et al.
American Journal of Surgery
|
August 7, 2022
Primary hyperparathyroidism after radioactive iodine therapy: Is it a distinct clinical entity?
Iuliana Bobanga, Judy Jin, Scott Wilhelm, et al.
Annals of Hematology
|
January 24, 2018
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma
Iris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, et al.
Cancer Research
|
December 21, 2006
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu, Yichen Cao, Charles Chen, et al.
Nature Reviews. Drug Discovery
|
October 4, 2006
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm, Christopher Carter, Mark Lynch, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
The Surgical Clinics of North America
|
May 27, 2014
Evaluation of thyroid incidentaloma
Scott Wilhelm
Current Pharmaceutical Design
|
October 9, 2002
BAY 43-9006: preclinical data
Scott Wilhelm, Du-Shieng Chien
Rare Tumors
|
July 20, 2011
Adrenal adenomatoid tumor in a patient with human immunodeficiency virus
Roy Phitayakorn, Gregory Maclennan, Peter Sadow, et al.
Seminars in Oncology
|
August 8, 2006
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway
Jared A Gollob, Scott Wilhelm, Chris Carter, et al.
International Journal of Surgical Pathology
|
March 13, 2026
Parathyroid Carcinoma Mimicking Thyroid Hyalinizing Trabecular Tumor: A Case Report and Review of Atypical Presentations of Parathyroid Carcinoma
Paola Loreto-Palacio, Myriam Decaussin-Petrucci, Scott Wilhelm, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
|
March 14, 2009
Utilization of preoperative patient factors to predict postoperative vitamin D deficiency for patients undergoing gastric bypass
Judy Jin, Thomas A Stellato, Peter T Hallowell, et al.
American Journal of Surgery
|
August 7, 2022
Primary hyperparathyroidism after radioactive iodine therapy: Is it a distinct clinical entity?
Iuliana Bobanga, Judy Jin, Scott Wilhelm, et al.
Annals of Hematology
|
January 24, 2018
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma
Iris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, et al.
Cancer Research
|
December 21, 2006
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu, Yichen Cao, Charles Chen, et al.
Nature Reviews. Drug Discovery
|
October 4, 2006
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm, Christopher Carter, Mark Lynch, et al.
Page
of 2